Gemma A Figtree, Stephen T Vernon, Jason A Harmer, Michael P Gray, Clare Arnott, Eric Bachour, Giannie Barsha, David Brieger, Alex Brown, David S Celermajer, Keith M Channon, Nicholas W S Chew, James J H Chong, Clara K Chow, Peter A Cistulli, Patrick T Ellinor, Stuart M Grieve, Tomasz J Guzik, Emil Hagström, Alicia Jenkins, Garry Jennings, Anthony C Keech, Katharine A Kott, Leonard Kritharides, Mamas A Mamas, Roxana Mehran, Peter J Meikle, Pradeep Natarajan, Kazuaki Negishi, John O'Sullivan, Sanjay Patel, Peter J Psaltis, Julie Redfern, Philippe G Steg, David R Sullivan, Johan Sundström, Birgit Vogel, Andrew Wilson, Dennis Wong, Deepak L Bhatt, Jason C Kovacic, Stephen J Nicholls
Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients...
September 26, 2023: Journal of the American College of Cardiology